Nanobiotix Files March 2025 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1760854
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
Nanobiotix filed its monthly 6-K, confirming it's a foreign private issuer filing 20-F.
AI Summary
Nanobiotix S.A. filed a Form 6-K on March 31, 2025, for the month of March 2025. The company, incorporated in France with its principal executive office in Paris, is a foreign private issuer that files annual reports under Form 20-F. This filing is routine and does not contain specific financial or operational updates beyond its periodic reporting status.
Why It Matters
This filing confirms Nanobiotix's ongoing compliance with SEC reporting requirements as a foreign private issuer, providing transparency to investors about its regulatory status.
Risk Assessment
Risk Level: low — This is a routine periodic filing by a foreign private issuer and does not contain new material information or significant financial events.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the Form 6-K
- Paris, France (location) — Principal executive office location
- 001-39777 (other) — SEC file number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that is made public in their home country, filed with a stock exchange, or distributed to their security holders.
What period does this Form 6-K cover?
This Form 6-K covers the month of March 2025.
Is Nanobiotix S.A. a U.S. or foreign company for SEC reporting purposes?
Nanobiotix S.A. is identified as a foreign private issuer.
What form does Nanobiotix S.A. use for its annual reports?
Nanobiotix S.A. files its annual reports under cover of Form 20-F.
Where is Nanobiotix S.A.'s principal executive office located?
Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding Nanobiotix S.A. (NBTX).